Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Man paralyzed after being hit with a Taser while running from police in Colorado sues officer
Alabama lawmakers adjourn session without final gambling vote
Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky
McIlroy says he and Adam Scott also involved in Saudi meetings
After Weinstein's case was overturned, New York considers strengthening sex crime prosecutions
A look at what passed and failed in the 2024 legislative session
College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
Trump is limited in what he can say about his court case. His GOP allies are showing up to help
Everybody may love Raymond, but Ray Romano loves Peter Boyle
FBI warns that foreign adversaries could use AI to spread disinformation about US elections